Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.
Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.
复制标题
DOI：
10.1158/0008-5472.can-11-3912
复制
发表时间：
2012-07-15
期刊：
影响因子：
11.2
通讯作者：
Jaffee EM
中科院分区：
文献类型：
--
作者：
Le DT;Jaffee EM
Regulatory T cells (Tregs) have become an important player in regulating anti-cancer immune responses. In fact, published studies describe a correlation between tumor infiltrating Tregs and poor prognosis. Once called “suppressor T cells”, these T cells evaded isolation due to a lack of known markers that distinguished them from other T cells. However, the biology of these T cells is currently a major focus of immunologic research. Markers have since been discovered that identify these T cells and provide insights into how these T cells are regulated. Despite these advances, much needs to be learned about the sub-sets of Tregs and their specific roles in regulating immune responses. In addition, specific agents that target Tregs are currently unavailable. Cyclophosphamide (CY) has emerged as a clinically feasible agent that can suppress Tregs and allow more effective induction of antitumor immune responses. This review will focus on the use of CY in targeting Tregs to augment cancer vaccine approaches. However, these principles can also be applied to other immunotherapy strategies.
